Drug Profile
Dezapelisib - Incyte Corporation
Alternative Names: INCB-40093; INCB040093Latest Information Update: 15 May 2017
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Antineoplastics; Purines; Pyrimidinones; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hodgkin's disease; Non-Hodgkin's lymphoma
Most Recent Events
- 08 May 2017 Incyte corporation terminates a phase II trial in Hodgkin's disease (Monotherapy, Combination therapy, Second-line therapy or greater, Recurrent) in USA (PO) (NCT02456675) due to the changing treatment landscape for the development of new agents in combination in Hodgkin lymphoma
- 01 Jan 2017 Incyte corporation completes a phase-II trial in Hodgkin's disease (Monotherapy, Combination therapy, Second-line therapy or greater, Recurrent) in USA (PO) (NCT02456675)
- 12 Dec 2016 Chemical structure information added